GH Form 4: Director Meghan Joyce adds 66 shares, now holds 11,216

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) – SEC Form 4 filing dated 07/07/2025

Director Meghan V. Joyce reported the acquisition of 66 common shares on 07/04/2025 through the settlement of previously granted Restricted Stock Units (RSUs). The RSUs carried a $0 conversion price, so no cash changed hands. Following the transaction, Joyce’s direct beneficial ownership increases to 11,216 common shares.

The underlying RSU award vested 25 % on 08/04/2022, with the remaining 75 % vesting in equal monthly installments over three years (through 08/04/2025). No derivative securities were disposed of, and the transaction was coded “M” (acquisition from the company without open-market purchase).

The filing is routine, involves a small share count relative to Guardant Health’s outstanding shares, and contains no financial performance information or strategic disclosures.

Positive

• Insider continues to increase ownership, potentially aligning director incentives with shareholder interests.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine RSU vesting—minimal market impact, indicates continued director alignment.

The Form 4 shows Director Meghan Joyce taking delivery of 66 shares from vested RSUs at no cost, lifting her direct stake to 11,216 shares. The award’s vesting mechanics were already disclosed, so the transaction is unsurprising. The small share count (<1 % of daily volume) limits signaling value, yet continued insider ownership can be viewed positively for governance. No shares were sold, so there is no selling pressure signal. Overall, the filing is neutral for valuation or liquidity considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Joyce Meghan V.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/04/2025		M		66	A	$0	11,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/04/2025		M			66	(1)	(2)	Common Stock	66	$0	67	D

Explanation of Responses:

1. The restricted stock unit vested 25% of the shares subject to such award on August 4, 2022. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of August 4, 2022 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Meghan Verena Joyce	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health's (GH) latest Form 4 report?

Director Meghan V. Joyce acquired 66 common shares via RSU vesting on 07/04/2025.

How many GH shares does Meghan Joyce now own?

After the transaction, she owns 11,216 common shares directly.

Was any cash paid for the shares?

No. The RSUs converted at a $0 exercise price, so no cash outlay occurred.

Does the filing indicate any share sales?

No shares were sold; the transaction code "M" reflects only the acquisition of shares from an equity award.

When will the remaining RSUs vest?

The award vests monthly through August 4, 2025, completing the three-year schedule.